drugset
Drugs / Peginterferon Alfa-2a (40KD)
last change Sep 2009 re-read 9 days ago

Peginterferon Alfa-2a (40KD)

also known as PEGASYS
Developed for
chronic hepatitis B virus infection · chronic hepatitis C virus infection
Investigated by
Baqiyatallah Medical Sciences University · Baqiyatallah Research Center for Gastroenterology and Liver Diseases · Guilan University of Medical Sciences · Hoffmann-La Roche · Tabriz Research Center for Gastroenterology and Liver Diseases · Tehran Hepatitis Center

Trials 2

today NCT00460850 · Ph 4 NCT00707850 · Ph 4
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 42 trials
Phase 4 NCT00460850 Sep 2007 → Jun 2008 chronic hepatitis B virus infection Hoffmann-La Roche Terminated No outcome recorded Stop: Enrollment
Phase 4 NCT00707850 May 2007 → Sep 2009 chronic hepatitis C virus infection, thalassemia Baqiyatallah Medical Sciences University Completed No outcome recorded
Comparator or background therapy1 trial
Phase 4 NCT00707772 Comparator Mar 2007 → Sep 2009 chronic hepatitis C virus infection, hemophilia Baqiyatallah Medical Sciences University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as peginterferon alfa-2a (40KD) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00460850 ↗
2

NCT00707850 ↗

NCT00707772 ↗
Known as PEGASYS “PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)” NCT00707772 ↗
2

“PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)” NCT00707850 ↗

“peginterferon alfa-2a (40KD) [PEGASYS]” NCT00460850 ↗
Route Subcutaneous “180 micrograms sc weekly for 48 weeks” NCT00460850 ↗